BEIJING, Nov. 26, 2024 — Phil Rivers Technology today announced that its breakthrough candidate drug PR00012 has received clinical trial approval from the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE). This milestone marks a significant advancement in potential treatment options for pancreatic cancer and other solid tumors.

The approved Phase I clinical trial is an open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of PR00012. Notably, the drug targets a unique mechanism not currently addressed by existing therapies.

Breakthrough AI-Driven Drug Research and Development

Leveraging its proprietary "Artificial Intelligence for Science (AI4S) + Disease" platform, guided by the principles of computational medicine, Phil Rivers Technology developed PR00012 in less than two years—a remarkable achievement in drug discovery. The company's innovative approach uses artificial intelligence and real-world patient data to create digital disease models, enabling more precise targeting and development.

"The primary challenge in treating pancreatic cancer lies in understanding its complex mechanisms," said Dr. Jianfei "Jeff" Yang, Chief Scientific Officer. "Our “AI4S+Disease” platform allows us to comprehensively analyze disease mechanisms and identify promising therapeutic targets through advanced computational methods."

Preclinical studies have demonstrated PR00012's excellent drug-like properties, stability, and significant therapeutic potential. The company plans to use its AI platform to further refine patient selection and optimize clinical trial enrollment criteria.

About Phil Rivers Technology

Phil Rivers Technology is a platform-based innovation company that leverages artificial intelligence to accelerate drug discovery. Focused on "AI+Disease" driven research, the company develops computational medicine solutions, discovers new drug targets, and simulates clinical trials.